The 17th Annual Pain Therapeutics Summit

The 17th Annual Pain Therapeutics Summit serves as a catalyst for collaboration between academia, industry, and regulatory bodies, fostering a multidisciplinary exchange of ideas, expertise, and resources. Gain invaluable insights from renowned experts, network with key stakeholders, and stay at the forefront of emerging trends and breakthroughs in pain drug development.

URL:
Tickets: https://go.evvnt.com/1803826-0?pid=10018

Prices:
Industry: USD 1395.00,
Academic/Government: USD 695.00,
Post-Doctoral Scholar: USD 495.00,
Student: USD 395.00

Speakers: Rebecca Baker, Ph.D. Director, HEAL Initiative NINDS, National Institutes of Health , Mary Ann Pelleymounter, Ph.D. Program Director, NINDS, Division of Translational Research, National Institutes of Health , Neil Singla, MD Chief Scientific Officer, Lotus Clinical Research , Kaitlin Roberson, EdM Co-founder and CEO, Cacti Therapeutics, Jeff Gudin, MD Faculty, Department of Anesthesiology and Pain Management University of Miami, Miller School of Medicine , Praveen Anand, MD Professor of Clinical Neurology, Imperial College London, Ryan Lanier, Ph.D. Director, Clinical Development and Abuse Liability, Pinney Associates , Becky Klein, Ph.D. (tentative) Director, Merck Sharp and Dohme, Hernan Bazan, MD Chief Executive Officer and Co-Founder, South Rampart Pharma , Shoshana Lipson Executive Director, Hope in Pain , DP Mohapatra, Ph.D. Program Director for Pain, NINDS/National Institutes of Health, Jeff Reich, MD Co-Founder, CEO, Sparian Biosciences , Ram Arudchandran, Ph.D. Program Director, National Institute of Neurological Disorders and Stroke, Aakanksha Jain, Ph.D. Senior Postdoctoral Fellow, Harvard University , Cindy Steinberg National Director of Policy and Advocacy, US Pain Foundation , James Hackworth, Ph.D. James Hackworth, Ph.D. President, Brand Division, Tris Pharma